查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602816

抗体生产市场：按抗体类型、製程和最终用户划分 - 2025-2030 年全球预测

Antibody Production Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Process (Downstream Processing, Filtration, Upstream Processing), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗体生产市场价值为179.7亿美元，预计到2024年将达到201.6亿美元，复合年增长率为12.40%，到2030年将达到407.7亿美元。

抗体生产市场涉及用于治疗、诊断和研究等各种用途的抗体的生产和精製。慢性病的增加、创新药物的开发以及对准确诊断工具的需求（其应用范围从癌症治疗到自体免疫疾病）都加剧了对该市场的需求。抗体生产的主要最终用途领域包括生物製药公司、临床实验室和研究机构。关键的成长要素包括生技的进步、研发投资的增加以及个人化医疗的进步。例如，人工智慧和机器学习在药物发现过程中的持续整合正在推动抗体生产的创新和效率。开发抗体治疗方法来对抗感染疾病和探索神经退化性疾病，以满足紧迫的全球健康需求，也存在新的机会。

主要市场统计
基准年[2023] 179.7亿美元
预测年份 [2024] 201.6亿美元
预测年份 [2030] 407.7亿美元
复合年增长率（%） 12.40%

然而，挑战依然存在，包括抗体生产的复杂性和高成本、监管障碍以及对熟练人员的需求。知识产权问题和竞争性市场压力使成长更加复杂。供应链中断和严格的合规标准也阻碍了市场动力。为了克服这些挑战，促进学术机构和生技公司之间的合作将促进创新。预计未来将出现技术创新的领域包括增强抗体药物偶联物和双特异性抗体。此外，在传统治疗领域之外探索单株抗体的潜力可以开闢新的市场途径。

简而言之，抗体生产市场充满了由技术进步和医疗需求驱动的成长机会，但为了维持成长，企业必须在人才开拓、简化生产流程和遵守法规方面进行策略性投资。平衡创新、效率和监管合规性对于有效利用市场潜力至关重要。

市场动态：揭示快速发展的抗体生产市场的关键市场洞察

供需的动态交互作用正在改变抗体生产市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人口中慢性病盛行率上升
    • 对标靶治疗和个人化药物的需求不断增长
    • 医疗基础设施现代化和医疗费用上涨
  • 市场限制因素
    • 与抗体生产相关的高成本
  • 市场机会
    • 积极进行研究活动，推出新型植物单株抗体
    • 双特异性抗体在癌症免疫治疗的新用途
  • 市场问题
    • 抗体生产的严格法律规范

波特五力：驾驭抗体生产市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解抗体生产市场的外部影响

外部宏观环境因素在塑造抗体生产市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解抗体生产市场的竞争格局

对抗体生产市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：抗体生产市场供应商绩效评估

FPNV定位矩阵是评估抗体生产市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製抗体生产市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对抗体生产市场进行策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中慢性病盛行率不断上升
      • 对标靶治疗和个人化医疗的需求不断增长
      • 医疗基础设施现代化和医疗费用上涨
    • 抑制因素
      • 与抗体生产相关的高成本
    • 机会
      • 积极的研究活动旨在引入新的植物来源单株抗体
      • 双特异性抗体在癌症免疫治疗的新用途
    • 任务
      • 抗体生产的严格法规结构
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 抗体生产市场：按抗体类型

  • 介绍
  • 单株抗体
  • 多株抗体

第七章 抗体生产市场：依製程分类

  • 介绍
  • 下游工艺
    • 层析法树脂
    • 层析法系统
  • 滤
    • 耗材及配件
    • 过滤系统
  • 上游过程
    • 反应器
    • 消耗品

第八章抗体生产市场：依最终用户分类

  • 介绍
  • 合约研究组织（CRO）
  • 诊断实验室
  • 製药和生物技术公司
  • 研究所和学术中心

第九章 北美和南美抗体生产市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗体生产市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲抗体生产市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cell Signaling Technology, Inc.
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Fibercell Systems Inc
  • GE HealthCare Technologies Inc.
  • Genmab A/S
  • GenScript BIoTech Corporation
  • Gilead Sciences, Inc.
  • INTEGRA Biosciences AG
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pall Corporation
  • Pfizer Inc.
  • ProteoGenix
  • Sanofi SA
  • Sartorius AG
  • Teva Pharmaceutical Industries Ltd.
  • The Antibody Company
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0EA

The Antibody Production Market was valued at USD 17.97 billion in 2023, expected to reach USD 20.16 billion in 2024, and is projected to grow at a CAGR of 12.40%, to USD 40.77 billion by 2030.

The antibody production market involves the creation and refinement of antibodies for various applications, including therapeutics, diagnostics, and research. The necessity of this market is underscored by the rising prevalence of chronic diseases, innovative drug development, and the need for precise diagnostic tools, with applications spanning from cancer treatment to autoimmune disorders. Major end-use areas for antibody production include biopharmaceutical companies, clinical laboratories, and research institutions. Key growth factors include advancements in biotechnology, increased R&D investment, and the evolving landscape of personalized medicine. For instance, the ongoing integration of AI and machine learning in drug discovery processes is driving innovation and efficiency in antibody production. Emerging opportunities also exist in developing therapeutic antibodies to tackle infectious diseases and in exploring neurodegenerative conditions, responding to pressing global health needs.

KEY MARKET STATISTICS
Base Year [2023] USD 17.97 billion
Estimated Year [2024] USD 20.16 billion
Forecast Year [2030] USD 40.77 billion
CAGR (%) 12.40%

However, challenges persist, such as the complexity and high cost of antibody production, regulatory hurdles, and the need for skilled personnel. Intellectual property concerns and competitive market pressures further complicate growth. The supply chain disruptions and stringent compliance standards can also hinder market momentum. To navigate these challenges, fostering collaborations between academic institutions and biotechnology firms can expedite innovation. Looking forward, areas ripe for innovation include enhancing antibody-drug conjugates and bispecific antibodies, which promise higher specificity and efficacy in treatments. Additionally, exploring the potential of monoclonal antibodies in non-traditional therapeutic areas can open new market avenues.

In essence, while the antibody production market is ripe with opportunities driven by technological advancements and medical needs, companies must strategically invest in talent development, streamline production processes, and remain adaptable to regulatory changes to sustain growth. Achieving a balanced approach in innovation, efficiency, and regulatory compliance will be imperative for leveraging market potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Production Market

The Antibody Production Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing demand for targeted therapies and personalized medicines
    • Modernization of healthcare infrastructure and increase in healthcare expenditure
  • Market Restraints
    • High costs associated with antibody production
  • Market Opportunities
    • Robust research activities to introduce novel plant-made monoclonal antibody
    • Emerging applications of bispecific antibodies in cancer immunotherapy
  • Market Challenges
    • Stringent regulatory frameworks for antibody production

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Production Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Production Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Production Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Production Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Production Market

A detailed market share analysis in the Antibody Production Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Production Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Production Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Production Market

A strategic analysis of the Antibody Production Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Antibody Type, market is studied across Monoclonal Antibodies and Polyclonal Antibodies.
  • Based on Process, market is studied across Downstream Processing, Filtration, and Upstream Processing. The Downstream Processing is further studied across Chromatography Resins and Chromatography Systems. The Filtration is further studied across Consumables & Accessories and Filtration Systms. The Upstream Processing is further studied across Bioreactors and Consumables.
  • Based on End-User, market is studied across Contract Research Organizations (CROs), Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research Institutes & Academic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing demand for targeted therapies and personalized medicines
      • 5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with antibody production
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
      • 5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for antibody production
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Production Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.2.1. Chromatography Resins
    • 7.2.2. Chromatography Systems
  • 7.3. Filtration
    • 7.3.1. Consumables & Accessories
    • 7.3.2. Filtration Systms
  • 7.4. Upstream Processing
    • 7.4.1. Bioreactors
    • 7.4.2. Consumables

8. Antibody Production Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations (CROs)
  • 8.3. Diagnostic Laboratories
  • 8.4. Pharmaceutical & Biotechnology Companies
  • 8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Production Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Biogen Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Cell Signaling Technology, Inc.
  • 7. Eppendorf AG
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Fibercell Systems Inc
  • 10. GE HealthCare Technologies Inc.
  • 11. Genmab A/S
  • 12. GenScript Biotech Corporation
  • 13. Gilead Sciences, Inc.
  • 14. INTEGRA Biosciences AG
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Pall Corporation
  • 19. Pfizer Inc.
  • 20. ProteoGenix
  • 21. Sanofi S.A.
  • 22. Sartorius AG
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. The Antibody Company
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY PRODUCTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 279. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023